Back to results

A Study to Investigate the Effect of Severely Diminished Liver Function on the Metabolism, Safety, and Tolerability of a Single Oral Dose of Enzalutamide in Men

Primary Purpose

Severe Hepatic Impairment, Normal Hepatic Function

Status

Completed

Phase

Phase 1

Locations

Bulgaria

Study Type

Interventional

Intervention

enzalutamide

About this trial

This is an interventional basic science trial for Severe Hepatic Impairment focused on measuring Phase 1, Pharmacokinetics, Safety, Severe hepatic impairment, Enzalutamide

Eligibility Criteria

18 Years - 69 Years (Adult, Older Adult)MaleAccepts Healthy Volunteers

Inclusion Criteria:

Male subject and their female spouse/partners who are of childbearing potential must be using highly effective contraception consisting of two forms of birth control starting at Screening and continue throughout the study period and for 90 days after the final study drug administration.
Male subject must not donate sperm starting at Screening and throughout the study period and for 90 days after the final study drug administration.
Subject has a Body Mass Index (BMI) range of 18.5 - 34.0 kg/m2 inclusive. The subject weighs at least 50 kg [at Screening].

Inclusion Criteria:Subjects with severe hepatic impairment must also meet the following inclusion criteria:

Subject has a Child-Pugh classification Class C (severe, 10 to 15 points).

Inclusion Criteria: For Healthy Subjects Only:

Age- and BMI-matched to subjects with severe liver hepatic impairment.

Exclusion Criteria:

Subject has known or suspected hypersensitivity to enzalutamide, or any components of the formulation used.
Subject has history of seizure or any condition that may predispose to seizure. Also history of loss of consciousness or transient ischemic attack within 12 months of enrollment (Day 1 visit).
Subject has used grapefruit (or grapefruit containing products) or marmalade in the week prior to admission to the clinical unit (Day -1), as reported by the subject.

Exclusion Criteria: For Healthy Subjects Only:

Subject has any of the liver function tests above the upper limit of normal.

Exclusion Criteria: Subjects with severe hepatic impairment must also not have any of the following characteristics:

Subject has fluctuating or rapidly deteriorating hepatic function, as indicated by strongly varying or worsening of clinical and/or laboratory signs of hepatic impairment within the screening period.
Subject has surgical porto-systemic shunts, including TIPSS (Trans-jugular intrahepatic portosystemic shunt).
Subject has presence of severe hepatic encephalopathy (grade > 2).
Subject has advanced ascites.
Subject has esophageal variceal bleeding in the medical history (within 6 months before Day -1).
Subject has thrombocyte level below 40x109 /L and /or hemoglobin below 90 g/L.
Subject has significant renal dysfunction (creatinine clearance below 50 mL/min, estimated according to the method of Modification of Diet in Renal Disease (MDRD) formula).
Subject has had previous liver transplantation.

Sites / Locations

Comac Medical Ltd.

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Arm Label

1:Single dose of enzalutamide in hepatically impaired subjects

2:Single dose of enzalutamide in healthy subjects

Arm Description

Single dose of enzalutamide

Outcomes

Primary Outcome Measures

Pharmacokinetics (PK) of enzalutamide after a single oral dose

area under the plasma concentration - time curve (AUC) extrapolated to infinity (AUC0-inf)

PK of enzalutamide after a single oral dose

maximum concentration (observed) (Cmax)

PK of enzalutamide plus N-desmethyl enzalutamide (M2) after a single oral dose

area under the plasma concentration - time curve (AUC) extrapolated to infinity (AUC0-inf)

PK of enzalutamide plus N-desmethyl enzalutamide (M2) after a single oral dose

maximum concentration (observed) (Cmax)

Secondary Outcome Measures

PK of enzalutamide, M1, M2 and the sum of enzalutamide plus N-desmethyl enzalutamide (M2)

Cmax and AUC0-inf (M1, M2 only), time to attain Cmax (tmax), AUC up to last quantifiable concentration (AUC0-last), apparent terminal elimination half life (t1/2), apparent volume of distribution during the terminal phase after extra vascular dosing (Vz/F), apparent total body clearance after extra vascular dosing (CL/F) (parent compound only), Metabolite-to-Parent Ratio (MPR), percent extrapolated for AUC0-inf (%AUC)

Additional pharmacokinetic variables for enzalutamide, and, as appropriate, for M1 and M2, based upon unbound plasma concentrations

Unbound Cmax (Cmax,u), unbound AUC0-inf (AUC0-inf,u), and unbound AUC0-last (AUC0-last,u). Unbound CL/F (CLu/F) and unbound Vz/F (Vz,u/F) (parent only)

Full Information

NCT ID

NCT02138162

First Posted

May 12, 2014

Last Updated

May 12, 2014

Sponsor

Astellas Pharma Europe B.V.

Collaborators

Medivation, Inc.

1. Study Identification

Unique Protocol Identification Number

NCT02138162

Brief Title

A Study to Investigate the Effect of Severely Diminished Liver Function on the Metabolism, Safety, and Tolerability of a Single Oral Dose of Enzalutamide in Men

Official Title

A Phase 1, Non-randomized, Open-label, Single-dose Study to Investigate the Pharmacokinetics, Safety and Tolerability of Enzalutamide in Male Subjects With Severe Hepatic Impairment and Normal Hepatic Function

Study Type

Interventional

2. Study Status

Record Verification Date

May 2014

Overall Recruitment Status

Completed

Study Start Date

August 2013 (undefined)

Primary Completion Date

March 2014 (Actual)

Study Completion Date

March 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

Astellas Pharma Europe B.V.

Collaborators

Medivation, Inc.

4. Oversight

Data Monitoring Committee

5. Study Description

Brief Summary

The influence of severely diminished liver function on the metabolism, safety, and tolerability of a single oral dose of enzalutamide in a group of 8 men. The results are compared to the data gained from 8 age- and BMI-matched men with normal liver function.

Detailed Description

Screening takes place between Day -22 and Day -2, and subjects are admitted to the clinic on Day -1. Each subject receives a single oral dose of enzalutamide on Day 1, under fasted conditions. They are discharged on Day 7; ambulant visits take place until Day 50. An End of Study Visit (ESV) occurs 7-10 days after the last PK sampling or early withdrawal. Full PK profiles are obtained for enzalutamide, metabolite 1 of enzalutamide (M1) and metabolite 2 of enzalutamide (M2) up to 1176 hours (Day 50) after administration. Safety assessments are performed throughout the study. For subjects with severe hepatic impairment, additional Child-Pugh classification and laboratory safety tests (including liver function tests) are performed regularly after administration.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Severe Hepatic Impairment, Normal Hepatic Function

Keywords

Phase 1, Pharmacokinetics, Safety, Severe hepatic impairment, Enzalutamide

7. Study Design

Primary Purpose

Basic Science

Study Phase

Phase 1

Interventional Study Model

Parallel Assignment

Masking

None (Open Label)

Allocation

Non-Randomized

Enrollment

16 (Actual)

8. Arms, Groups, and Interventions

Arm Title

1:Single dose of enzalutamide in hepatically impaired subjects

Arm Type

Experimental

Arm Description

Single dose of enzalutamide

Arm Title

2:Single dose of enzalutamide in healthy subjects

Arm Type

Experimental

Arm Description

Single dose of enzalutamide

Intervention Type

Drug

Intervention Name(s)

enzalutamide

Other Intervention Name(s)

ASP9785,, MDV3100,, Xtandi

Intervention Description

oral

Primary Outcome Measure Information:

Title

Pharmacokinetics (PK) of enzalutamide after a single oral dose

Description

area under the plasma concentration - time curve (AUC) extrapolated to infinity (AUC0-inf)

Time Frame